false 0001738021 0001738021 2024-06-13 2024-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

 

 

 

COMPASS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-39696 82-4876496
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

 

(617) 500-8099

(Registrant's telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:    
     
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value per share CMPX NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 13, 2024 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Form DEF 14A, filed with the U.S. Securities and Exchange Commission on April 29, 2024.

 

Proposal No. 1. Election of Directors. The stockholders elected the two Class I nominees for director to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below:

 

            Broker Non-
Name   For   Withheld   votes
Ellen V. Chiniara, J.D.   76,766,213   23,754,485   17,705,143
Mary Ann Gray, Ph.D.   100,051,792   468,906   17,705,143

 

Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, by the votes set forth in the table below:

 

            Broker Non-
For Against   Abstained   votes
118,180,952   13,785   31,104   0

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Compass Therapeutics, Inc.
   
Date: June 17, 2024 By: /s/ NEIL LERNER
    Neil Lerner
    VP of Finance

 

 

 

v3.24.1.1.u2
Cover
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Entity File Number 001-39696
Entity Registrant Name COMPASS THERAPEUTICS, INC.
Entity Central Index Key 0001738021
Entity Tax Identification Number 82-4876496
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 80 Guest Street
Entity Address, Address Line Two Suite 601
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02135
City Area Code (617)
Local Phone Number 500-8099
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CMPX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Compass Therapeutics (NASDAQ:CMPX)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more Compass Therapeutics Charts.
Compass Therapeutics (NASDAQ:CMPX)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more Compass Therapeutics Charts.